HEADER ISOMERASE/IMMUNOSUPPRESSANT 11-OCT-04 1XQ7 TITLE CYCLOPHILIN FROM TRYPANOSOMA CRUZI BOUND TO CYCLOSPORIN A CAVEAT 1XQ7 ABA D 6 C-ALPHA IS PLANAR COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEPTIDYL-PROLYL CIS-TRANS ISOMERASE; COMPND 3 CHAIN: A, B, C; COMPND 4 SYNONYM: PPIASE, ROTAMASE, CYCLOPHILIN A; COMPND 5 EC: 5.2.1.8; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: CYCLOSPORIN A; COMPND 9 CHAIN: D, E, F; COMPND 10 SYNONYM: CYCLOSPORINE, CICLOSPORIN, CICLOSPORINE; COMPND 11 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: TRYPANOSOMA CRUZI; SOURCE 3 ORGANISM_TAXID: 5693; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_STRAIN: BL21 STAR; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: BG1861; SOURCE 9 MOL_ID: 2; SOURCE 10 SYNTHETIC: YES; SOURCE 11 ORGANISM_SCIENTIFIC: TOLYPOCLADIUM INFLATUM 2; SOURCE 12 ORGANISM_TAXID: 29910 KEYWDS ISOMERASE-IMMUNOSUPPRESSANT COMPLEX, CYCLOPHILIN-CYCLOSPORIN COMPLEX, KEYWDS 2 CYCLOSPORIN A, IMMUNOSUPPRESSANT, CYCLOPHILIN, STRUCTURAL GENOMICS, KEYWDS 3 PROTEIN STRUCTURE INITIATIVE, PSI, STRUCTURAL GENOMICS OF PATHOGENIC KEYWDS 4 PROTOZOA CONSORTIUM, SGPP EXPDTA X-RAY DIFFRACTION AUTHOR J.M.CARUTHERS,W.G.J.HOL,STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA AUTHOR 2 CONSORTIUM (SGPP) REVDAT 7 31-JAN-18 1XQ7 1 JRNL REVDAT 6 27-JUL-11 1XQ7 1 REMARK REVDAT 5 13-JUL-11 1XQ7 1 VERSN REVDAT 4 24-FEB-09 1XQ7 1 VERSN REVDAT 3 28-NOV-06 1XQ7 1 REMARK REVDAT 2 16-MAY-06 1XQ7 1 COMPND REVDAT 1 21-DEC-04 1XQ7 0 JRNL AUTH J.M.CARUTHERS,W.G.J.HOL, JRNL AUTH 2 STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA CONSORTIUM JRNL TITL CYCLOPHILIN FROM TRYPANOSOMA CRUZI BOUND TO CYCLOSPORIN A JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 2.07 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.1.24 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 49.39 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 94.4 REMARK 3 NUMBER OF REFLECTIONS : 29952 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.172 REMARK 3 R VALUE (WORKING SET) : 0.169 REMARK 3 FREE R VALUE : 0.235 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1590 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.07 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.12 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2185 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2360 REMARK 3 BIN FREE R VALUE SET COUNT : 107 REMARK 3 BIN FREE R VALUE : 0.3130 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4068 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 288 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 25.08 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.27000 REMARK 3 B22 (A**2) : 1.16000 REMARK 3 B33 (A**2) : 0.03000 REMARK 3 B12 (A**2) : 0.72000 REMARK 3 B13 (A**2) : -0.62000 REMARK 3 B23 (A**2) : -0.11000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.214 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.193 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.143 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 5.403 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.961 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.919 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4147 ; 0.023 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 5589 ; 2.056 ; 1.970 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 526 ; 7.560 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): NULL ; NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 627 ; 0.154 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3088 ; 0.009 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1998 ; 0.248 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 258 ; 0.176 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 50 ; 0.257 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 11 ; 0.121 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2623 ; 1.093 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 4218 ; 1.933 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1524 ; 3.360 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1371 ; 5.451 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1XQ7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 12-OCT-04. REMARK 100 THE DEPOSITION ID IS D_1000030637. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 22-SEP-04 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.998 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : ELVES REMARK 200 DATA SCALING SOFTWARE : ELVES REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 29952 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.070 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.800 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.4 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.07 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.12 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.2 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: EPMR REMARK 200 STARTING MODEL: 1XO7, CYCLOPHILIN REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.31 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.48 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 50MM POTASSIUM PHOSPHATE, 40% PEG REMARK 280 8000, 2MM CYCLOSPORIN A, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 25K, TEMPERATURE 298K, PH 8 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 990 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8120 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -8.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1000 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 7980 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1000 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 7990 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 THE CYCLOSPORIN A IS CYCLIC PEPTIDE, A MEMBER OF IMMUNOSUPPRESSANT REMARK 400 CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: D, E, F REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. CYCLIZATION REMARK 400 IS ACHIEVED BY LINKING THE N- AND THE C- TERMINI. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 CD LYS A 132 O HOH B 2027 2.08 REMARK 500 O HOH C 2001 O HOH C 2003 2.15 REMARK 500 O HOH B 2021 O HOH B 2053 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 11 CB - CG - OD2 ANGL. DEV. = 7.4 DEGREES REMARK 500 ARG A 57 NE - CZ - NH1 ANGL. DEV. = 3.6 DEGREES REMARK 500 ARG A 57 NE - CZ - NH2 ANGL. DEV. = -3.4 DEGREES REMARK 500 ASP A 124 CB - CG - OD2 ANGL. DEV. = 5.7 DEGREES REMARK 500 LEU A 150 CA - CB - CG ANGL. DEV. = 20.1 DEGREES REMARK 500 ASP B 30 CB - CG - OD2 ANGL. DEV. = 6.1 DEGREES REMARK 500 ASP B 73 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP B 87 CB - CG - OD2 ANGL. DEV. = 6.8 DEGREES REMARK 500 ASP B 162 CB - CG - OD2 ANGL. DEV. = 7.0 DEGREES REMARK 500 ASP C 6 CB - CG - OD2 ANGL. DEV. = 9.2 DEGREES REMARK 500 ASP C 16 CB - CG - OD2 ANGL. DEV. = 6.2 DEGREES REMARK 500 ASP C 152 CB - CG - OD2 ANGL. DEV. = 7.4 DEGREES REMARK 500 BMT D 5 CA - C - N ANGL. DEV. = 15.2 DEGREES REMARK 500 ABA D 6 C - N - CA ANGL. DEV. = 21.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 16 -12.40 93.74 REMARK 500 PHE A 62 -84.83 -133.61 REMARK 500 ASP A 73 10.12 -142.24 REMARK 500 ASN A 151 44.39 33.85 REMARK 500 PHE B 62 -75.01 -146.00 REMARK 500 ASP B 73 10.79 -155.81 REMARK 500 ASN B 89 117.12 -162.15 REMARK 500 ASP C 16 -13.11 81.79 REMARK 500 PHE C 62 -82.92 -145.94 REMARK 500 ASP C 73 6.00 -152.22 REMARK 500 THR C 120 55.15 -142.34 REMARK 500 ASN C 151 -75.70 -86.31 REMARK 500 ASP C 152 56.99 -174.24 REMARK 500 VAL D 9 103.77 81.52 REMARK 500 MLE E 2 69.10 -119.17 REMARK 500 MLE E 10 143.66 76.74 REMARK 500 MLE F 10 146.33 80.60 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASN C 151 ASP C 152 146.34 REMARK 500 SAR E 7 MLE E 8 146.21 REMARK 500 MLE E 8 VAL E 9 -144.59 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN D OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN E OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN F OF CYCLOSPORIN A REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1XO7 RELATED DB: PDB REMARK 900 CYCLOPHILIN FROM TRYPANOSOMA CRUZI REMARK 900 RELATED ID: TCRU013382AAA RELATED DB: TARGETDB REMARK 900 RELATED ID: 1BCK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 C REMARK 900 RELATED ID: 1C5F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CSA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1CWA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 1CWB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 1CWC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 D REMARK 900 RELATED ID: 1CWH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A MODIFIED AT POSITION 7 REMARK 900 RELATED ID: 1CWI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITION 7 REMARK 900 RELATED ID: 1CWJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH NODIFIED REMARK 900 CYCLOSPORIN C AT POSITIONS 1, AND 9 REMARK 900 RELATED ID: 1CYA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WIYH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYB RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1IKF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CTCLOSPORIN-FAB COMPLEX REMARK 900 RELATED ID: 1M63 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX REMARK 900 RELATED ID: 1MF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN REMARK 900 CYCLOPHILIN AND CYCLOSPORIN A REMARK 900 RELATED ID: 1MIK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 6 REMARK 900 RELATED ID: 1QNG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1QNH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE REMARK 900 MUTANT) COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2ESL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2OJU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN J COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2POY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM IOWA II CYCLOPHILIN A REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2RMA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2RMB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 2RMC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2WFJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2X2C RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2X7K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2Z6W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3BO7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII REMARK 900 COMPLEXED WIT CYCLOSPORIN A REMARK 900 RELATED ID: 3CYS RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3EOV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED REMARK 900 WITH CYCLOSPORIN A DBREF 1XQ7 A 2 166 UNP Q4DPB9 Q4DPB9_TRYCR 30 194 DBREF 1XQ7 B 2 166 UNP Q4DPB9 Q4DPB9_TRYCR 30 194 DBREF 1XQ7 C 2 166 UNP Q4DPB9 Q4DPB9_TRYCR 30 194 DBREF 1XQ7 D 1 11 NOR NOR00033 NOR00033 1 11 DBREF 1XQ7 E 1 11 NOR NOR00033 NOR00033 1 11 DBREF 1XQ7 F 1 11 NOR NOR00033 NOR00033 1 11 SEQRES 1 A 166 MET PRO VAL VAL THR ASP LYS VAL TYR PHE ASP ILE THR SEQRES 2 A 166 ILE GLY ASP GLU PRO VAL GLY ARG VAL VAL ILE GLY LEU SEQRES 3 A 166 PHE GLY ASN ASP VAL PRO LYS THR VAL GLU ASN PHE LYS SEQRES 4 A 166 GLN LEU ALA SER GLY GLU ASN GLY PHE GLY TYR LYS GLY SEQRES 5 A 166 SER ILE PHE HIS ARG VAL ILE ARG ASN PHE MET ILE GLN SEQRES 6 A 166 GLY GLY ASP PHE THR ASN PHE ASP GLY THR GLY GLY LYS SEQRES 7 A 166 SER ILE TYR GLY THR ARG PHE ASP ASP GLU ASN LEU LYS SEQRES 8 A 166 ILE LYS HIS PHE VAL GLY ALA VAL SER MET ALA ASN ALA SEQRES 9 A 166 GLY PRO ASN SER ASN GLY SER GLN PHE PHE VAL THR THR SEQRES 10 A 166 ALA PRO THR PRO TRP LEU ASP GLY ARG HIS VAL VAL PHE SEQRES 11 A 166 GLY LYS VAL VAL GLU GLY MET ASP VAL VAL LYS LYS VAL SEQRES 12 A 166 GLU ASN THR LYS THR GLY LEU ASN ASP LYS PRO LYS LYS SEQRES 13 A 166 ALA VAL LYS ILE ASN ASP CYS GLY VAL LEU SEQRES 1 B 166 MET PRO VAL VAL THR ASP LYS VAL TYR PHE ASP ILE THR SEQRES 2 B 166 ILE GLY ASP GLU PRO VAL GLY ARG VAL VAL ILE GLY LEU SEQRES 3 B 166 PHE GLY ASN ASP VAL PRO LYS THR VAL GLU ASN PHE LYS SEQRES 4 B 166 GLN LEU ALA SER GLY GLU ASN GLY PHE GLY TYR LYS GLY SEQRES 5 B 166 SER ILE PHE HIS ARG VAL ILE ARG ASN PHE MET ILE GLN SEQRES 6 B 166 GLY GLY ASP PHE THR ASN PHE ASP GLY THR GLY GLY LYS SEQRES 7 B 166 SER ILE TYR GLY THR ARG PHE ASP ASP GLU ASN LEU LYS SEQRES 8 B 166 ILE LYS HIS PHE VAL GLY ALA VAL SER MET ALA ASN ALA SEQRES 9 B 166 GLY PRO ASN SER ASN GLY SER GLN PHE PHE VAL THR THR SEQRES 10 B 166 ALA PRO THR PRO TRP LEU ASP GLY ARG HIS VAL VAL PHE SEQRES 11 B 166 GLY LYS VAL VAL GLU GLY MET ASP VAL VAL LYS LYS VAL SEQRES 12 B 166 GLU ASN THR LYS THR GLY LEU ASN ASP LYS PRO LYS LYS SEQRES 13 B 166 ALA VAL LYS ILE ASN ASP CYS GLY VAL LEU SEQRES 1 C 166 MET PRO VAL VAL THR ASP LYS VAL TYR PHE ASP ILE THR SEQRES 2 C 166 ILE GLY ASP GLU PRO VAL GLY ARG VAL VAL ILE GLY LEU SEQRES 3 C 166 PHE GLY ASN ASP VAL PRO LYS THR VAL GLU ASN PHE LYS SEQRES 4 C 166 GLN LEU ALA SER GLY GLU ASN GLY PHE GLY TYR LYS GLY SEQRES 5 C 166 SER ILE PHE HIS ARG VAL ILE ARG ASN PHE MET ILE GLN SEQRES 6 C 166 GLY GLY ASP PHE THR ASN PHE ASP GLY THR GLY GLY LYS SEQRES 7 C 166 SER ILE TYR GLY THR ARG PHE ASP ASP GLU ASN LEU LYS SEQRES 8 C 166 ILE LYS HIS PHE VAL GLY ALA VAL SER MET ALA ASN ALA SEQRES 9 C 166 GLY PRO ASN SER ASN GLY SER GLN PHE PHE VAL THR THR SEQRES 10 C 166 ALA PRO THR PRO TRP LEU ASP GLY ARG HIS VAL VAL PHE SEQRES 11 C 166 GLY LYS VAL VAL GLU GLY MET ASP VAL VAL LYS LYS VAL SEQRES 12 C 166 GLU ASN THR LYS THR GLY LEU ASN ASP LYS PRO LYS LYS SEQRES 13 C 166 ALA VAL LYS ILE ASN ASP CYS GLY VAL LEU SEQRES 1 D 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 E 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 F 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA HET DAL D 1 5 HET MLE D 2 9 HET MLE D 3 9 HET MVA D 4 8 HET BMT D 5 13 HET ABA D 6 6 HET SAR D 7 5 HET MLE D 8 9 HET MLE D 10 9 HET DAL E 1 5 HET MLE E 2 9 HET MLE E 3 9 HET MVA E 4 8 HET BMT E 5 13 HET ABA E 6 6 HET SAR E 7 5 HET MLE E 8 9 HET MLE E 10 9 HET DAL F 1 5 HET MLE F 2 9 HET MLE F 3 9 HET MVA F 4 8 HET BMT F 5 13 HET ABA F 6 6 HET SAR F 7 5 HET MLE F 8 9 HET MLE F 10 9 HETNAM DAL D-ALANINE HETNAM MLE N-METHYLLEUCINE HETNAM MVA N-METHYLVALINE HETNAM BMT 4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SAR SARCOSINE FORMUL 4 DAL 3(C3 H7 N O2) FORMUL 4 MLE 12(C7 H15 N O2) FORMUL 4 MVA 3(C6 H13 N O2) FORMUL 4 BMT 3(C10 H19 N O3) FORMUL 4 ABA 3(C4 H9 N O2) FORMUL 4 SAR 3(C3 H7 N O2) FORMUL 7 HOH *288(H2 O) HELIX 1 1 VAL A 31 GLY A 44 1 14 HELIX 2 2 THR A 120 ASP A 124 5 5 HELIX 3 3 GLY A 136 ASN A 145 1 10 HELIX 4 4 GLY A 149 LYS A 153 5 5 HELIX 5 5 VAL B 31 GLY B 44 1 14 HELIX 6 6 THR B 120 ASP B 124 5 5 HELIX 7 7 GLY B 136 ASN B 145 1 10 HELIX 8 8 GLY B 149 LYS B 153 5 5 HELIX 9 9 VAL C 31 GLY C 44 1 14 HELIX 10 10 THR C 120 ASP C 124 5 5 HELIX 11 11 GLY C 136 ASN C 145 1 10 SHEET 1 AA 8 PHE A 55 ILE A 59 0 SHEET 2 AA 8 MET A 63 GLY A 66 -1 O MET A 63 N ILE A 59 SHEET 3 AA 8 PHE A 113 THR A 116 -1 O PHE A 113 N GLY A 66 SHEET 4 AA 8 ALA A 98 MET A 101 -1 O ALA A 98 N THR A 116 SHEET 5 AA 8 VAL A 129 GLU A 135 -1 N PHE A 130 O VAL A 99 SHEET 6 AA 8 GLU A 17 LEU A 26 -1 O VAL A 23 N VAL A 134 SHEET 7 AA 8 LYS A 7 ILE A 14 -1 O VAL A 8 N ILE A 24 SHEET 8 AA 8 VAL A 158 VAL A 165 -1 O LYS A 159 N THR A 13 SHEET 1 BA 8 PHE B 55 ILE B 59 0 SHEET 2 BA 8 MET B 63 GLY B 66 -1 O MET B 63 N ILE B 59 SHEET 3 BA 8 PHE B 113 THR B 116 -1 O PHE B 113 N GLY B 66 SHEET 4 BA 8 ALA B 98 MET B 101 -1 O ALA B 98 N THR B 116 SHEET 5 BA 8 VAL B 129 GLU B 135 -1 N PHE B 130 O VAL B 99 SHEET 6 BA 8 GLU B 17 LEU B 26 -1 O VAL B 23 N VAL B 134 SHEET 7 BA 8 LYS B 7 ILE B 14 -1 O VAL B 8 N ILE B 24 SHEET 8 BA 8 VAL B 158 VAL B 165 -1 O LYS B 159 N THR B 13 SHEET 1 CA 8 ARG C 57 ILE C 59 0 SHEET 2 CA 8 MET C 63 GLY C 66 -1 O MET C 63 N ILE C 59 SHEET 3 CA 8 PHE C 113 THR C 116 -1 O PHE C 113 N GLY C 66 SHEET 4 CA 8 ALA C 98 MET C 101 -1 O ALA C 98 N THR C 116 SHEET 5 CA 8 VAL C 129 GLU C 135 -1 N PHE C 130 O VAL C 99 SHEET 6 CA 8 GLU C 17 LEU C 26 -1 O VAL C 23 N VAL C 134 SHEET 7 CA 8 LYS C 7 ILE C 14 -1 O VAL C 8 N ILE C 24 SHEET 8 CA 8 VAL C 158 VAL C 165 -1 O LYS C 159 N THR C 13 LINK C DAL D 1 N MLE D 2 1555 1555 1.36 LINK N DAL D 1 C ALA D 11 1555 1555 1.34 LINK C MLE D 2 N MLE D 3 1555 1555 1.34 LINK C MLE D 3 N MVA D 4 1555 1555 1.33 LINK C BMT D 5 N ABA D 6 1555 1555 1.32 LINK C ABA D 6 N SAR D 7 1555 1555 1.32 LINK C SAR D 7 N MLE D 8 1555 1555 1.33 LINK C MLE D 8 N VAL D 9 1555 1555 1.32 LINK C VAL D 9 N MLE D 10 1555 1555 1.34 LINK C MLE D 10 N ALA D 11 1555 1555 1.33 LINK C DAL E 1 N MLE E 2 1555 1555 1.35 LINK N DAL E 1 C ALA E 11 1555 1555 1.35 LINK C MLE E 2 N MLE E 3 1555 1555 1.33 LINK C MLE E 3 N MVA E 4 1555 1555 1.34 LINK C BMT E 5 N ABA E 6 1555 1555 1.33 LINK C ABA E 6 N SAR E 7 1555 1555 1.33 LINK C SAR E 7 N MLE E 8 1555 1555 1.33 LINK C MLE E 8 N VAL E 9 1555 1555 1.33 LINK C VAL E 9 N MLE E 10 1555 1555 1.33 LINK C MLE E 10 N ALA E 11 1555 1555 1.34 LINK C DAL F 1 N MLE F 2 1555 1555 1.35 LINK N DAL F 1 C ALA F 11 1555 1555 1.33 LINK C MLE F 2 N MLE F 3 1555 1555 1.34 LINK C MLE F 3 N MVA F 4 1555 1555 1.34 LINK C MVA F 4 N BMT F 5 1555 1555 1.33 LINK C BMT F 5 N ABA F 6 1555 1555 1.34 LINK C ABA F 6 N SAR F 7 1555 1555 1.33 LINK C SAR F 7 N MLE F 8 1555 1555 1.35 LINK C MLE F 8 N VAL F 9 1555 1555 1.33 LINK C VAL F 9 N MLE F 10 1555 1555 1.33 LINK C MLE F 10 N ALA F 11 1555 1555 1.34 CISPEP 1 BMT D 5 ABA D 6 0 24.08 SITE 1 AC1 12 ARG A 57 PHE A 62 GLN A 65 GLY A 74 SITE 2 AC1 12 ALA A 102 ASN A 103 ALA A 104 GLN A 112 SITE 3 AC1 12 PHE A 114 TRP A 122 HIS A 127 ALA C 104 SITE 1 AC2 17 HOH A2064 HOH A2066 ARG B 57 PHE B 62 SITE 2 AC2 17 GLN B 65 GLY B 74 ALA B 102 ASN B 103 SITE 3 AC2 17 GLN B 112 PHE B 114 TRP B 122 LEU B 123 SITE 4 AC2 17 HIS B 127 HOH B2047 HOH B2049 HOH E2001 SITE 5 AC2 17 HOH E2002 SITE 1 AC3 18 TRP A 122 ALA B 104 ARG C 57 PHE C 62 SITE 2 AC3 18 GLN C 65 GLY C 74 ALA C 102 ASN C 103 SITE 3 AC3 18 GLN C 112 PHE C 114 TRP C 122 HIS C 127 SITE 4 AC3 18 HOH F2001 HOH F2002 HOH F2003 HOH F2004 SITE 5 AC3 18 HOH F2005 HOH F2006 CRYST1 52.269 57.059 58.807 110.49 108.21 105.40 P 1 3 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019132 0.005270 0.009971 0.00000 SCALE2 0.000000 0.018178 0.009755 0.00000 SCALE3 0.000000 0.000000 0.020316 0.00000 MASTER 476 0 27 11 24 0 13 6 0 0 0 42 END